scholarly journals Recurrent checkpoint inhibitor‐induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma

2020 ◽  
Vol 95 (7) ◽  
Author(s):  
Steven R. Hwang ◽  
Timothy O'Dowd ◽  
Svetomir N. Markovic ◽  
Alexandra P. Wolanskyj‐Spinner
Keyword(s):  
Metastatic Melanoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Checkpoint Inhibitor

scholarly journals Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy

2016 ◽  
Vol 9 (3) ◽  
pp. 691-697 ◽  
Author(s):  
Amruth R. Palla ◽  
Devin Kennedy ◽  
Hossain Mosharraf ◽  
Donald Doll
Keyword(s):  
Lung Cancer ◽  
Hemolytic Anemia ◽  
Immune Checkpoint ◽  
Autoimmune Hemolytic Anemia ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Cell Cancer ◽  
Metastatic Malignant Melanoma ◽  
Metastatic Lung ◽  
Third Line

Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic protocols for first-, second-, or third-line agents for these metastatic cancers. Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al.: BMC Med 2016;14: 20], metastatic non-small cell lung cancer [Guibert and Mazières: Expert Opin Biol Ther 2015;15: 1789–1797], metastatic renal cell cancer [Farolfi et al.: Expert Opin Drug Metab Toxicol 2016;12: 1089–1096], and relapsed or refractory classic Hodgkin’s lymphoma [Villasboas and Ansell: Expert Rev Anticancer Ther 2016;16: 5–12]. Given the current and increasing indications for these drugs, it is essential for all physicians to become well versed with their common adverse effects and to be observant for other less documented clinical conditions that could be unmasked with the use of such medications. A definite association between autoimmune hemolytic anemia and the immune checkpoint inhibitor nivolumab has not been clearly documented, although a few cases have been reported recently [Kong et al.: Melanoma Res 2016;26: 202–204; Schwab et al.: Case Rep Oncol 2016;9: 373–378; Tardy et al.: Hematol Oncol 2016, DOI: 10.1002/hon.2338]. We report a case of fatal autoimmune hemolytic anemia refractory to steroids in a patient treated with nivolumab for metastatic lung cancer, and reflect on the other reported cases of autoimmune hemolytic anemia after the use of nivolumab.

scholarly journals A Case of Lung Adenocarcinoma with Autoimmune Hemolytic Anemia Developing After Immune Checkpoint Inhibitor Treatment

Haigan ◽  
2021 ◽  
Vol 61 (7) ◽  
pp. 975-978
Author(s):  
Naoki Takata ◽  
Kenta Kambara ◽  
Kotaro Tokui ◽  
Chihiro Taka ◽  
Seisuke Okazawa ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Hemolytic Anemia ◽  
Immune Checkpoint ◽  
Autoimmune Hemolytic Anemia ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

2016 ◽  
Vol 26 (2) ◽  
pp. 202-204 ◽  
Author(s):  
Benjamin Y. Kong ◽  
Kenneth P. Micklethwaite ◽  
Sanjay Swaminathan ◽  
Richard F. Kefford ◽  
Matteo S. Carlino
Keyword(s):  
Metastatic Melanoma ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia

1975 ◽  
Vol 135 (10) ◽  
pp. 1293-1300 ◽  
Author(s):  
J. V. Dacie
Keyword(s):  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

Giant cell hepatitis and Coomb’s positive autoimmune hemolytic anemia: a case report and literature review

2014 ◽  
Vol 25 (1) ◽  
Author(s):  
Hasan M. Isa ◽  
◽  
Lina F. Al Ali ◽  
Afaf M. Mohamed ◽  
Rawia M. Hamad ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Giant Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Giant Cell Hepatitis

Anti‐plasma cell treatment in refractory autoimmune hemolytic anemia in a child with multivisceral transplant

2021 ◽  
Author(s):  
Shahira Ghobrial ◽  
Corina Elena Gonzalez ◽  
Stuart Kaufman ◽  
Nada Yazigi ◽  
Cal Matsumoto ◽  
...  
Keyword(s):  
Hemolytic Anemia ◽  
Plasma Cell ◽  
Autoimmune Hemolytic Anemia

scholarly journals No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 475
Author(s):  
Michele Guida ◽  
Nicola Bartolomeo ◽  
Pietro Quaglino ◽  
Gabriele Madonna ◽  
Jacopo Pigozzo ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Checkpoint Inhibitor ◽  
Progression Free Survival ◽  
Nras Mutation ◽  
Disease Free Interval ◽  
Free Survival ◽  
Mutational Status ◽  
Metastatic Sites ◽  
Disease Free ◽  
Mutant Braf

Aims: It is debated whether the NRAS-mutant melanoma is more aggressive than NRAS wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169 wt/wt. We compared the two cohorts regarding the characteristics of primary and metastatic disease, disease-free interval (DFI) and outcome to CII. No substantial differences were observed between the two groups at melanoma onset, except for a more frequent ulceration in the wt/wt group (p = 0.03). Also, the DFI was very similar in the two cohorts. In advanced disease, we only found lung and brain progression more frequent in the wt/wt group. Regarding the outcomes to CII, no significant differences were reported in overall response rate (ORR), disease control rate (DCR), progression free survival (PFS) or overall survival (OS) (42% versus 37%, 60% versus 59%, 12 (95% CI, 7–18) versus 9 months (95% CI, 6–16) and 32 (95% CI, 23–49) versus 27 months (95% CI, 16–35), respectively). Irrespectively of mutational status, a longer OS was significantly associated with normal LDH, <3 metastatic sites, lower white blood cell and platelet count, lower neutrophil-to-lymphocyte (N/L) ratio. Our data do not show increased aggressiveness and higher responsiveness to CII in NRAS-mutant MM.

Sign in / Sign up

Export Citation Format

Share Document